{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:17:38Z","timestamp":1787912258290,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"DOI":"10.7759\/cureus.115338","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:48:02Z","timestamp":1787910482000},"source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Challenges in Metastatic Non-small Cell Lung Cancer (NSCLC) With Concurrent Mesenchymal-Epithelial Transition Factor (MET) Amplification and High Programmed Death-Ligand 1 (PD-L1) Expression: A Case Study"],"prefix":"10.7759","author":[{"given":"Md. Arifur","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasin Mesbah Bin","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad S","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masud","family":"Parvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman Reza","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1241402","article-title":"Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments","volume":"13","author":"Yang M","year":"2023","unstructured":"Yang M, Mandal E, Liu FX, O'Hara RM Jr, Lesher B, Sanborn RE. Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments. Front Oncol. 2023, 13:1241402. 10.3389\/fonc.2023.1241402","journal-title":"Front Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours - molecular diagnosis and targeted therapy","volume":"17","author":"Guo R","year":"2020","unstructured":"Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A. MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol. 2020, 17:569-87. 10.1038\/s41571-020-0377-z","journal-title":"Nat Rev Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0759-9","article-title":"MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer","volume":"12","author":"Wang Q","year":"2019","unstructured":"Wang Q, Yang S, Wang K, Sun SY. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019, 12:63. 10.1186\/s13045-019-0759-9","journal-title":"J Hematol Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00918-6","article-title":"Mutational landscape and expression of PD-L1 in patients with non-small cell lung cancer harboring genomic alterations of the MET gene","volume":"17","author":"Fischer A","year":"2022","unstructured":"Fischer A, Bankel L, Hiltbrunner S, et al.. Mutational landscape and expression of PD-L1 in patients with non-small cell lung cancer harboring genomic alterations of the MET gene. Target Oncol. 2022, 17:683-94. 10.1007\/s11523-022-00918-6","journal-title":"Target Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100319","article-title":"Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung\u00a0cancer","volume":"6","author":"Coleman N","year":"2021","unstructured":"Coleman N, Hong L, Zhang J, Heymach J, Hong D, Le X. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung\u00a0cancer. ESMO Open. 2021, 6:100319. 10.1016\/j.esmoop.2021.100319","journal-title":"ESMO Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.03.012","article-title":"A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape Project","volume":"131","author":"Kerr KM","year":"2019","unstructured":"Kerr KM, Thunnissen E, Dafni U, et al.. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Lung Cancer. 2019, 131:95-103. 10.1016\/j.lungcan.2019.03.012","journal-title":"Lung Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy334","article-title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","volume":"29","author":"Sabari JK","year":"2018","unstructured":"Sabari JK, Leonardi GC, Shu CA, et al.. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018, 29:2085-91. 10.1093\/annonc\/mdy334","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13887","article-title":"Systematic review of PD-1\/PD-L1 inhibitors in oncology: from personalized medicine to public health","volume":"26","author":"Chang E","year":"2021","unstructured":"Chang E, Pelosof L, Lemery S, et al.. Systematic review of PD-1\/PD-L1 inhibitors in oncology: from personalized medicine to public health. Oncologist. 2021, 26:e1786-99. 10.1002\/onco.13887","journal-title":"Oncologist"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae006","article-title":"Impact of increasing PD-L1 levels on outcomes to PD-1\/PD-L1 inhibition in patients with NSCLC: a pooled analysis of 11 prospective clinical trials","volume":"29","author":"Vallejo J","year":"2024","unstructured":"Vallejo J, Singh H, Larkins E, et al.. Impact of increasing PD-L1 levels on outcomes to PD-1\/PD-L1 inhibition in patients with NSCLC: a pooled analysis of 11 prospective clinical trials. Oncologist. 2024, 29:422-30. 10.1093\/oncolo\/oyae006","journal-title":"Oncologist"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28045","article-title":"Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver","volume":"12","author":"Dom\u00e8nech M","year":"2021","unstructured":"Dom\u00e8nech M, Mu\u00f1oz Marmol AM, Mate JL, et al.. Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver. Oncotarget. 2021, 12:1802-10. 10.18632\/oncotarget.28045","journal-title":"Oncotarget"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.12.004","article-title":"Prognostic impact of TP53 mutations in metastatic nonsquamous non-small-cell lung cancer","volume":"25","author":"Mathiot L","year":"2024","unstructured":"Mathiot L, Nigen B, Goronflot T, et al.. Prognostic impact of TP53 mutations in metastatic nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2024, 25:244-53.e2. 10.1016\/j.cllc.2023.12.004","journal-title":"Clin Lung Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.017","article-title":"Genetic heterogeneity of MET-aberrant NSCLC and its impact on the outcome of immunotherapy","volume":"16","author":"Kron A","year":"2021","unstructured":"Kron A, Scheffler M, Heydt C, et al.. Genetic heterogeneity of MET-aberrant NSCLC and its impact on the outcome of immunotherapy. J Thorac Oncol. 2021, 16:572-82. 10.1016\/j.jtho.2020.11.017","journal-title":"J Thorac Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol33050258","article-title":"Overcoming acquired MET-driven resistance to first-line lorlatinib: successful combination of lorlatinib and envafolimab in an ALK-positive NSCLC patient with ultra-high PD-L1 expression","volume":"33","author":"Ding L","year":"2026","unstructured":"Ding L, Nuersulitan R, Wang J, Chen H, Zhuo M. Overcoming acquired MET-driven resistance to first-line lorlatinib: successful combination of lorlatinib and envafolimab in an ALK-positive NSCLC patient with ultra-high PD-L1 expression. Curr Oncol. 2026, 33:258. 10.3390\/curroncol33050258","journal-title":"Curr Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024194","article-title":"Meta-analysis of P53 expression and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer","volume":"100","author":"Lin S","year":"2021","unstructured":"Lin S, Li X, Lin M, Yue W. Meta-analysis of P53 expression and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer. Medicine (Baltimore). 2021, 100:e24194. 10.1097\/MD.0000000000024194","journal-title":"Medicine (Baltimore)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24455","article-title":"Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer","volume":"9","author":"Albitar M","year":"2018","unstructured":"Albitar M, Sudarsanam S, Ma W, et al.. Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer. Oncotarget. 2018, 9:13682-93. 10.18632\/oncotarget.24455","journal-title":"Oncotarget"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf J","year":"2020","unstructured":"Wolf J, Seto T, Han JY, et al.. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020, 383:944-57. 10.1056\/NEJMoa2002787","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.010","article-title":"Crizotinib in patients with MET-amplified NSCLC","volume":"16","author":"Camidge DR","year":"2021","unstructured":"Camidge DR, Otterson GA, Clark JW, et al.. Crizotinib in patients with MET-amplified NSCLC. J Thorac Oncol. 2021, 16:1017-29. 10.1016\/j.jtho.2021.02.010","journal-title":"J Thorac Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.77652","article-title":"Severe hepatotoxicity from capmatinib: a case report and therapeutic approach","volume":"17","author":"Aiad M","year":"2025","unstructured":"Aiad M, Bhalala HJ, Bagshaw H, Starner S, Saha D. Severe hepatotoxicity from capmatinib: a case report and therapeutic approach. Cureus. 2025, 17:e77652. 10.7759\/cureus.77652","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231173120","article-title":"Severe hepatotoxicity during treatment with capmatinib","volume":"29","author":"Valencia Soto CM","year":"2023","unstructured":"Valencia Soto CM, Mart\u00ednez Callejo V, Garc\u00eda-Avello Fern\u00e1ndez-Cueto A, et al.. Severe hepatotoxicity during treatment with capmatinib. J Oncol Pharm Pract. 2023, 29:1484-8. 10.1177\/10781552231173120","journal-title":"J Oncol Pharm Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-176","article-title":"MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report","volume":"11","author":"Choi W","year":"2022","unstructured":"Choi W, Jeong KC, Park SY, Kim S, Kang EH, Hwang M, Han JY. MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report. Transl Lung Cancer Res. 2022, 11:1967-72. 10.21037\/tlcr-22-176","journal-title":"Transl Lung Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/517092-therapeutic-challenges-in-metastatic-non-small-cell-lung-cancer-nsclc-with-concurrent-mesenchymal-epithelial-transition-factor-met-amplification-and-high-programmed-death-ligand-1-pd-l1-expression-a-case-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:48:03Z","timestamp":1787910483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/517092-therapeutic-challenges-in-metastatic-non-small-cell-lung-cancer-nsclc-with-concurrent-mesenchymal-epithelial-transition-factor-met-amplification-and-high-programmed-death-ligand-1-pd-l1-expression-a-case-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.115338","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}